Figure 3
Estimated effect of current uric acid value on the hazard of death before kidney failure, Panel (A) Estimated effect of current uric acid value on the hazard of death before kidney failure adjusted for age, sex, primary kidney disease, hypertension, diabetes, cardiovascular disease, dyslipidemia, body mass index, albuminuria, CKD stage, medication adherence, use of renin-angiotensin system inhibitors, urate lowering therapy, spironolactone and anti-platelet agents, all at baseline (Model 1 in Table 3); Panel (B) Estimated effect of baseline uric acid value on the hazard of death before kidney failure, adjusted for the same factors as in (A) (Model 3 in Table 3). The reference value of uric acid for the HR indicated in the y-axis was arbitrarily chosen at 5 mg/gl, which corresponds to the midpoint of the normal range of uric acid (uric acid in mg/dl to µmol/l: × 59.48). Results from cause-specific Cox models using a spline function for uric acid. CKD-REIN cohort, France, 2013–2018 (n = 2344, including 218 death before kidney failure).
